Erectile dysfunction. Epidemiology, physiology, aetiology, diagnosis and therapy;Erektile funktionsstörungen: Epidemiologie, physiologie, ätiologie, diagnostik und therapie

Nervenarzt

Volumn 75, Issue 6, 2004, Pages 595-607

  Derouet, H ^a   Osterhage, J ^a   Sittinger, H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Diagnosis; Erectile dysfunction; PDE 5 inhibitors; Therapy; Vascular diagnosis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; DOPAMINE RECEPTOR BLOCKING AGENT; MOXISYLYTE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; PROSTAVASIN; SILDENAFIL; TADALAFIL; VARDENAFIL; YOCON GLENWOOD; YOHIMBINE;

COMORBIDITY; ERECTILE DYSFUNCTION; HORMONE SUBSTITUTION; HUMAN; MALE; PENIS PROSTHESIS; PSYCHOTHERAPY; REVIEW; VACUUM;

ADMINISTRATION, ORAL; HUMANS; IMPOTENCE; MALE; PATIENT CARE MANAGEMENT; PHOSPHODIESTERASE INHIBITORS; PRACTICE GUIDELINES; PSYCHOTHERAPY; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 3042809620     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Angulo J, Cuevas P, Fernandez A et al. (2001) Characterization of Vardenafil, a new PDES inhibitor for erectile dysfunction, and comparison of activity with sildenafil. Int J Imp Res 13(S4): 24 (p-64)
2. Arentewicz G, Schmidt G (Hrsg) (1993) Sexuell gestörte Beziehungen, Konzept und Technik der Paartherapie. Enke, Stuttgart
3. Bartolo DCC, Jarratt JA, Read NW (1983) The use of conventional electromyography to assess external shincter neuropathy. J Neurol Neurosurg Psychiatry 46: 1115-1118
4. Beier KM, Bosinski HAG, Hartmann U, Loewit K (Hrsg) (2001) Sexualmedizin, Urban & Fischer, München
5. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U (2000) Epidemiology of erectile dysfunction: results of the, Cologne male Survey. Int J Imp Res 12: 305-311
6. Breza J, Aboseif SR, Orvis BR et al. (1989) Detailed anatomy of penile neurovascular structures: Surgical significance. J Urol 141: 437-443
7. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ (1996) Sildenafil, an novel effective oral therapy for male erectile dysfunction. Br J Urol 78: 257-261
8. Brock G, Padma-Nathan H, Seger M (2002) Efficacy and tolerability of vardenafil in males with erectile dysfunction following radical prostatectomy. Eur Urol 51: 152
9. Brock GB, Mcmahon CG, Chen KK, Watkins V, Anglin G, Watkins S (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 168 (4): 1332-1336
10. Buddeberg C (1996) Sexualberatung. Enke, Stuttgart
11. Derouet H, Caspari D, Rohde V et al. (1999) Treatment of erectile dysfunction with external vacuum devices. Andrologia 31 (S1): 89-94
12. Derouet H, Nolden W, Jost WH, Osterhage J, Eckert R, Ziegler M (1998) Treatment of erectile dysfunction by an externous ischiocavernous muscle stimulator. Eur Urol 34 (4): 355-359
13. Eardley I, Edwards A, Hole J, Macdonagh R, Wright P (2003) Comparative efficacy of sildenafil citrate and apomorphine in men with erectile dysfunction: A randomised crossover study. Int J Impot Res 15(S6): 3
14. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mckinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151: 54-61
15. Foreman MM, Wernicke JF (1990). Approaches for the development of oral drug therapies for erectile dysfunction. Semin Urol 8: 107-112
16. Goldstein AMB, Padma-Nathan, H (1990) The microarchitecture of the intracavernosal smooth muscle and the cavernosal fibrous skeleton. J Urol 144: 1144-1146
17. Goldstein I, Young J, Segerson T, Thibonnier M (2002) Long-term efficacy and safety of Vardenafil in diabetic men with erectile dysfunction. Diabetes 51(S2): A98
18. Guiliano F, Chevret-Measson M, Tsatsaris A, Reitz C, Murino M, Thonneau P (2002) Prevalence of erectile dysfunction: results of an epidemiological survey of a representative sample of 1004 men. Eur Urol 42: 382-389
19. Hartmann U (1997) Psychological subtypes of erectile dysfunctions: results from statistical analyses and clinical practice. World J Urol 15: 56-64
20. Hartmann U (2000) Psychosomatische Aspekte bei Erektionsstörungen. Dtsch Ärztebl 97: B-534-538
21. Heaton JPW (2000) Apomorphine: an update of clinical trials. Int J Impot Res 12(S4): 67-73
22. Hoyndorf S, Christmann F (1998) Kognitive Verhaltenstherapie bei sexuellen Funktionsstörungen. In: Hautzinger M (Hrsg.) Kognitive Verhaltenstherapie bei psychischen Störungen, Beltz Psychologie Verlags Union, Weinheim
23. Kim N, Hang Y, Moreland R, Kwak S (2000) Cross-regulation of intracellular cGMP and cAMP in cultured human corpus cavernosum smooth muscle cells. Mol Cell Biol Res Comm 4: 10-14
24. Kiff ES, Swash M (1984) Normal proximal and delayed distal conduction in the pudendal nerves of patients with idiopathic (neurogenic) faecal incontinence. Br J Surg 71 614-616
25. Kirby M, Jackson G, Betteridge J, Friedli K (2001) Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract 55 (9): 614-618
26. Lewis R, Jordan G (2002) Surgery for erectile dysfunction. In: Campbells, Urology, 8th edn, vol-2. Saunders, Philadelphia
27. Kockott G (2002) Diagnostik und Therapie sexueller Funktionsstö rungen. In: Hartwich P, Haas S (Hrsg) Sexuelle Störungen und Probleme bei psychisch Kranken. Wissenschaft & Praxis, Sternenfels
28. Lizza EF, Rosen RC (1999) Definition and classification of erectile dysfunction. Report of the Nomenclature committee of the International society of impotence Research. Int J Impotence Res 11: 141-143
29. Lue TF, Tanagho EA (1988) Functional anatomy and mechanism of penile erection in the treatment of venogenic impotence. In: Tanagho EA, Lue TF, Mcclure RD (eds) Contemporary management of male impotence and infertility. Williams & Wilkins, Baltimore, pp-65-69
30. Michal V, Simana J, Rehak J, Masin J (1983) Haemodyna0mics of erection in man. Physiologia Bohemoslovaca 32: 497-499
31. Montorsi F et al. (2000) AMS Three-Piece Inflatable Implants for erectile dysfunction: A long-term Multi-institutional study in 200 consecutive patients. Eur Urol 37: 50-55
32. Montorsi F et al. (2003) Tadalafil in the treatment of ED following bilateral nerve-sparing radical retropubic prostatectomy. Int J Impot Res 15(S6): 4
33. NIH (1993) NIH Consensus Conference: impotence. NIH Consensus development panel on impotence. JAMA 270: 83
34. Opsomer RJ, Guerit JM, Wiese FX (1986) Pudendal cortical somatosensory evoked potentials. J Urol 135: 1216-1217
35. Padma-Nathan H, Hellstorm WJ, Kaiser FF et al. (1997) Treatment of men with erectile dysfunction with transurethral alprostadil Medicated Urethral system for erection (MUSE) Study group. N Engl J Med 336: 1-7
36. Porst H, Huebler D, Padma-Nathan H, Varense L, Anglin G, Giuliano F (2002) Tadalafil allows Men with erectile dysfunction to have sexual intercourse up to 36 hours postdose. Int J IMP Res 14(S4): S60
37. Porst H, Young JM, Schmidt AC, Buvat J, International Vardenafil Study Group (2003) efficacy and tolerability of vardenafil for erectile dysfunction in patient subgroups. Urology 6283: 519-523
38. Rampin O, Giuliano F (2001) Brain control of penile erection. World J Urol. 19: 1-8
39. Rendell MS, Rajfer J, Wicker PA, Smith MD (1999) Sildenafil for treatment of erectile dysfunction in men with diabetes-a randomized controlled trial. Sildenafil diabetes study group. JAMA 281: 421-426
40. Rosen RC, Leary M, Altwein J et al. (2002) LUTS and Male sexuality: Findings from the multi-national survey of the aging male (MSAM-7). Int J Imp Res 14(S3): S25
41. Rosen RC, Riley A, Wagner G et al. (1997) The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 49: 822-830
42. Rosen RC, Lane RM, Menace M (1999) Effects of SSRI's on sexual function: A critical review. J Clin Psychopharmacol 19: 67-85
43. Saenez de Tejada I, Emmick J, Anglin G, Fredlund P, Pullman W (2001) The effect of on demand Tadalafil (IC351) treatment of erectile dysfunction in men with diabetes. Eur Urol 39(S5): 16
44. Stief C, Ueckert S, Becker A et al. (2000) Effects of sildenafil on c-AMP and c-GMP levels in isolated human cavernous and cardiac tissue. Urology 55: 146-150
45. Wessels H, Lue TF, McAninch JW (1996) Penile length in the flaccid and erect states: Guidelines for penile augmentation. J Urol 156: 995-997
46. Yassin A, Diede HE, Saad F, Traish A (2003) Combination therapy of tadalafil and testosteron in hypogonadal non-responders. Int J Impot Res 15(S6): 27